Discontinuation report MYOCHRYSINE
Report ID | 86070 |
Drug Identification Number | 01927612 |
Brand name | MYOCHRYSINE |
Common or Proper name | Myochrysine 25mg |
Company Name | SANOFI-AVENTIS CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | GOLD SODIUM THIOMALATE |
Strength(s) | 25MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR |
Packaging size | 5 ampoules |
ATC code | M01CB |
ATC description | SPECIFIC ANTIRHEUMATIC AGENTS |
Reason for discontinuation | Other (Please describe in comments) |
Anticipated discontinuation date | |
Actual discontinuation date | 2019-06-04 |
Remaining supply date | 2017-12-01 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2019-06-10 | French | Compare |
v1 | 2019-06-10 | English | Compare |
Showing 1 to 2 of 2